Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
BMJ Case Reports
|
June 7, 2012
Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis
Sarah Keidel, Aubretia McColl, Sally Edmonds
Current Opinion in Immunology
|
March 5, 2013
ERAP1 and ankylosing spondylitis
Sarah Keidel, Liye Chen, Jennifer Pointon, et al.
BMC Musculoskeletal Disorders
|
November 24, 2017
The impact of rheumatologist-performed ultrasound on diagnosis and management of inflammatory arthritis in routine clinical practice
Stephen Kelly, Brian Davidson, Sarah Keidel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2024
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Yue Zhao, Zheyi Hu, Sai Praneeth Bathena, et al.
Arthritis and Rheumatism
|
May 12, 2012
Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis
Sravan K Payeli, Simon Kollnberger, Osiris Marroquin Belaunzaran, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Evan J Lipson, Sonia Dolfi, Hao Tang, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
BMJ Case Reports
|
June 7, 2012
Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis
Sarah Keidel, Aubretia McColl, Sally Edmonds
Current Opinion in Immunology
|
March 5, 2013
ERAP1 and ankylosing spondylitis
Sarah Keidel, Liye Chen, Jennifer Pointon, et al.
BMC Musculoskeletal Disorders
|
November 24, 2017
The impact of rheumatologist-performed ultrasound on diagnosis and management of inflammatory arthritis in routine clinical practice
Stephen Kelly, Brian Davidson, Sarah Keidel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2024
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Yue Zhao, Zheyi Hu, Sai Praneeth Bathena, et al.
Arthritis and Rheumatism
|
May 12, 2012
Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis
Sravan K Payeli, Simon Kollnberger, Osiris Marroquin Belaunzaran, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Evan J Lipson, Sonia Dolfi, Hao Tang, et al.
Page
of 2